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Abstract
Background: Treatment guidelines for generalized anxiety disorder (GAD) are based on a relatively small number
of randomized controlled trials and do not consider patient-centered perceptions of treatment helpfulness. We
investigated the prevalence and predictors of patient-reported treatment helpfulness for DSM-5 GAD and its two
main treatment pathways: encounter-level treatment helpfulness and persistence in help-seeking after prior
unhelpful treatment.
Methods: Data came from community epidemiologic surveys in 23 countries in the WHO World Mental Health
surveys. DSM-5 GAD was assessed with the fully structured WHO Composite International Diagnostic Interview
Version 3.0. Respondents with a history of GAD were asked whether they ever received treatment and, if so,
whether they ever considered this treatment helpful. Number of professionals seen before obtaining helpful
treatment was also assessed. Parallel survival models estimated probability and predictors of a given treatment
being perceived as helpful and of persisting in help-seeking after prior unhelpful treatment.
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Results: The overall prevalence rate of GAD was 4.5%, with lower prevalence in low/middle-income countries (2.8%) than
high-income countries (5.3%); 34.6% of respondents with lifetime GAD reported ever obtaining treatment for their GAD, with
lower proportions in low/middle-income countries (19.2%) than high-income countries (38.4%); 3) 70% of those who
received treatment perceived the treatment to be helpful, with prevalence comparable in low/middle-income countries and
high-income countries. Survival analysis suggested that virtually all patients would have obtained helpful treatment if they
had persisted in help-seeking with up to 10 professionals. However, we estimated that only 29.7% of patients would have
persisted that long. Obtaining helpful treatment at the person-level was associated with treatment type, comorbid panic/
agoraphobia, and childhood adversities, but most of these predictors were important because they predicted persistence
rather than encounter-level treatment helpfulness.
Conclusions: The majority of individuals with GAD do not receive treatment. Most of those who receive treatment regard it
as helpful, but receiving helpful treatment typically requires persistence in help-seeking. Future research should focus on
ensuring that helpfulness is included as part of the evaluation. Clinicians need to emphasize the importance of persistence
to patients beginning treatment.
Keywords: Generalized anxiety disorder, Pathways to treatment, Patient-centered outcomes, Treatment helpfulness
Background
Generalized Anxiety Disorder (GAD) encompasses a
variety of symptoms including excessive worrying, rest-
lessness, irritability, difficulties in concentration, and
constantly feeling on edge. Among the anxiety disorders,
GAD is perhaps the least well researched or understood
in part because of multiple revisions of the diagnostic
criteria, consideration of the diagnosis as a “wastebasket”
category when other anxiety diagnoses could not made,
and because worrying was assumed a part of everyday
life and associated with minimal impairment. However,
GAD is now known now to be a significant disorder
with high prevalence and significant impairment and dis-
ability [1, 2]. Worldwide an estimated 3.7% of individuals
will have GAD in their lifetime [1]. The role and quality
of life impairments of GAD are comparable in magni-
tude to those of major depression and greater than those
associated with substance abuse disorders [3].
Randomized controlled trials (RCTs) have identified
effective pharmacological and psychosocial treatments
[4–7]. However, results from RCTs do not necessarily
translate into real-world settings and are largely re-
stricted to high-income countries (HICs) with little glo-
bal evaluation of the effects of treatment [8–10].
Moreover, RCTs have focused on symptom reduction as
the critical and sometimes the sole outcome. Yet, symp-
tom reduction does not necessarily equate with func-
tional improvement, quality of life, or feelings on the
part of the patient that they have been helped [11, 12].
Perceived helpfulness of treatment is a key construct
that may capture whether patients achieve personally
meaningful goals through treatment. Helpfulness is im-
portant in its own right, but also has a critical role in
treatment in that perceived helpfulness relates directly
to treatment adherence as well as to critical processes
that span diverse forms psychotherapy (e.g., the
therapeutic alliance, critical incidents during treatment,
openness of the therapist) [13–16]. Helpfulness as an
outcome of treatment has received little attention in
GAD trials [17]. The extent to which helpfulness is
achieved with treatment and whether this is achieved
initially as the patient traverses different treatments re-
main to be evaluated. Such research might help identify
unmet patient needs that can be targeted through policy
and service responses [14, 18, 19]. Patient-centered re-
search on perceived GAD treatment helpfulness may
also inform treatment guidelines for GAD, which are
currently based on a relatively small number of RCTs.
The likelihood of a help-seeking individual ever
obtaining helpful treatment is a joint function of two
treatment pathways: 1) the probability that a given treat-
ment provider will be helpful, and 2) the probability that
a patient will persist in help-seeking after prior unhelpful
treatment encounters. Research on these processes for
depression and posttraumatic stress disorder found that
the majority of patients who persisted after previous un-
helpful treatments eventually obtained helpful treat-
ments, but that only a minority persisted in help-seeking
after more than a few unsuccessful treatment encounters
[20, 21]. It is unknown whether these patterns also are
true for GAD. Decomposing treatment pathways for
GAD would answer this question and might also reveal
modifiable predictors of GAD treatment helpfulness and
persistence that could be the focus of treatment quality
improvement initiatives.
The present study evaluated the helpfulness of treat-
ment encounters and predictors and pathways leading to
helpfulness in national community epidemiological sam-
ples that included respondents with a history of GAD
who sought treatment for their GAD. The data come
from the World Mental Health (WMH) Survey Initiative
[22]. This is a coordinated series of general population
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surveys under the auspices of the World Health
Organization. Data were collected in 23 countries of
varying income levels. This data set provides a unique
opportunity to evaluate helpfulness internationally and
to investigate predictors and pathways of perceived treat-
ment response in countries varying in income levels.
Methods
Samples
The World Health Organization’s (WHO) World Mental
Health (WMH) surveys are a coordinated set of community
epidemiological surveys administered to probability samples
of the non-institutionalized household population in coun-
tries throughout the world (https://www.hcp.med.harvard.
edu/wmh/) [23]. Data for the current report came from 26
WMH surveys carried out in 23 countries – 9 in countries
classified by the World Bank as low/middle-income (Brazil,
Bulgaria [separate surveys carried out in 2002 and 2016],
Colombia, Colombia [Medellin], Iraq, Lebanon, Mexico, and
Peru) and 17 in countries classified as HICs (Argentina,
Australia, Belgium, France, Germany, Israel, Italy, Japan, the
Kingdom of Saudi Arabia, the Netherlands, New Zealand,
Northern Ireland, Poland, Portugal, Spain, Spain [Murcia],
and the United States). Response rates ranged from 45.9%
(France) to 97.2% (Colombia [Medellin]) and averaged 67.4%
across surveys (see eTable 1 for detailed survey
characteristics).
The interview schedule was developed in English and
translated into other languages using a standardized
WHO translation, back-translation, and harmonization
protocol [24]. Interviews were administered face-to-face
in respondents’ homes after obtaining informed consent
using procedures approved by local Institutional Review
Boards. To reduce respondent burden, interviews were
administered in two parts. Part I was administered to all
respondents and assessed core DSM-IV mental disor-
ders. Part II assessed additional disorders and correlates
and was administered to all respondents who met life-
time criteria for any Part I disorder and a probability
subsample of other Part I respondents [25].
Measures
Generalized anxiety disorder (GAD)
Lifetime history of GAD was assessed with the fully
structured WHO Composite International Diagnostic
Interview (CIDI) Version 3.0 [23]. In an evaluation car-
ried out in conjunction with the US WMH survey [26],
GAD diagnoses based on the CIDI had good concord-
ance with diagnoses based on blinded clinical reassess-
ments with the Structured Clinical Interview for DSM-
IV (SCID) [27]. A clinical reappraisal study in other
WMH surveys, although not evaluating GAD in isola-
tion, found good concordance between diagnoses based
on the CIDI and SCID for any 12-month anxiety
disorder including GAD [28]. Consistent with previous
studies that modified the CIDI GAD algorithm [1, 26,
29], we generated DSM-5 GAD diagnoses by removing
the DSM-IV hierarchical exclusion of a GAD diagnosis
when symptoms occur exclusively during a mood dis-
order [30]. Age of onset (AOO) of GAD was assessed
using probing methods demonstrated to improve dating
accuracy [31].
Perceived helpfulness of treatment for GAD
Respondents who met lifetime criteria for GAD were
asked whether they had ever “talk [ed] to a medical doc-
tor or other professional about their worry or anxiety”
and, if so, how old they were the first time they did so.
“Other professionals” were defined broadly to include
“psychologists, counselors, spiritual advisors, herbalists,
acupuncturists, and other healing professionals.” Re-
spondents who had ever spoken to a professional about
their GAD were asked whether they ever received treat-
ment they “considered helpful or effective” (emphasis in
original). If so, they were asked how many professionals
they ever talked to about their worry or anxiety “up to
and including the first time [they] ever got helpful treat-
ment”. Respondents who said they never received helpful
treatment were asked how many professionals they ever
talked to about their worry or anxiety.
Predictors of obtaining helpful treatment for GAD
In addition to age of onset of GAD (continuous), we
considered 5 classes of predictors of helpful treatment:
Socio-demographic characteristics included sex, marital
status (currently married, never married, or previously
married) at the time of first treatment, and education (in
quartiles defined by within-country distributions) at the
time of first treatment. Lifetime comorbid conditions in-
cluded other lifetime anxiety disorders (including panic
disorder or agoraphobia with/ without panic disorder,
post-traumatic stress disorder, specific phobia, and social
phobia), major depressive disorder, broadly defined bipo-
lar spectrum disorder [32], alcohol and/ or drug abuse,
and alcohol and/ or drug dependence but not abuse. Co-
morbid conditions were restricted to disorders with an
age-of-onset prior to the age at which the respondent
first sought treatment for GAD. All comorbid conditions
were assessed with the CIDI. Treatment type was defined
as a cross-classification of (i) whether the respondent re-
ported receiving medication, psychotherapy, or both, as
of the age of first GAD treatment; and (ii) the types of
treatment providers seen as of that age. Types of pro-
viders included mental health specialists (psychiatrist,
psychiatric nurse, psychologist, psychiatric social worker,
mental health counselor), primary care providers, human
services providers (social worker or counselor in a social
services agency, spiritual advisor), and complementary-
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alternative medicine (other type of healer or self-help
group). Treatment timing included a continuous variable
for length of delay in years between age of onset of GAD
and age of initially seeking treatment, and a dichotom-
ous measure for whether the respondent’s first attempt
to seek treatment occurred before or after the year 2000.
The year 2000 was the typical midpoint between the
start of observations and survey field dates. Childhood
adversities included retrospective reports of significant
stressors experienced during childhood, including family
dysfunction (physical or sexual abuse, neglect, parental
mental disorder, parental substance use disorder, paren-
tal criminal behavior, and family violence) and other ad-
versities (parental death, parental divorce, other loss of a
parent, physical illness, and economic adversity).
Analysis methods
The sample was limited to respondents with a history of
DSM-5 GAD treatment who sought treatment for the
disorder at some time in their life. Cases were limited to
those who first sought GAD treatment in 1990 or later
to reduce the potential effects of recall bias. To investi-
gate the two pathways of helpful treatment separately,
we used discrete-event survival analysis to calculate the
conditional and cumulative probabilities of: (i) obtaining
helpful treatment after seeing between 1 and 10 profes-
sionals; and (ii) persisting in help-seeking after obtaining
prior unhelpful treatment [33]. We followed respondents
up through 10 professionals in the total sample and in
HICs because this was the last number where at least
n = 30 respondents received treatment. However, in low/
middle-income countries (LMICs), we followed respon-
dents only up through 3 professionals seen because this
was the last number where at least n = 30 respondents
received treatment.
We then carried out parallel survival analyses of the
predictors of these two decomposed, encounter-level
outcomes using standard discrete-time methods and a
logistic link function [34], followed by a person-level
model of overall probability of ever obtaining helpful
treatment regardless of number of professionals seen
(composite outcome). This allowed us to investigate pre-
dictors of obtaining helpful treatment at the person level
and to investigate the extent to which these predictors
were important because they predicted differential help-
fulness at the encounter level, differential probability of
persisting after earlier unhelpful treatments, or both.
We also investigated possible interactions of each sig-
nificant person-level predictor with country income
group and historical time (beginning treatment in 1990–
1999 vs. 2000+) in an effort to examine the
generalizability of the findings. Because the WMH sam-
ple design used weighting and clustering in all countries,
all statistical analyses were carried out using the Taylor
series linearization method [35], a design-based method
implemented in the SAS 9.4 program [36]. Logistic re-
gression coefficients and +/− 2 of their design-based
standard errors were exponentiated to create odds-ratios
(ORs) and 95% confidence intervals (CIs) (with odds ra-
tios less than 1 indicating lower likelihood, and odds ra-
tios greater than 1 indicating greater likelihood, of the
relevant association). Significance of sets of coefficients
was evaluated with Wald χ2 tests based on design-
corrected coefficient variance-covariance matrices. Stat-
istical significance was evaluated using two-sided,
design-based .05 level tests.
Results
GAD prevalence, treatment, and perceived helpfulness of
treatment
Lifetime prevalence (SE) of GAD was 2.8% (0.1) in
LMICs, 5.3% (0.1) in HICs, and 4.5% (0.1) across all
WMH surveys (Table 1). Among respondents with life-
time GAD, approximately one-third reported ever
obtaining GAD treatment (34.6% [0.8]) and 70.0% (1.4)
of those who obtained GAD treatment perceived the
treatment to be helpful. Respondents with GAD in
LMICs were significantly less likely than those in HICs
to obtain GAD treatment (19.2% vs. 38.4%; χ21 = 63.6,
p < 0.001), but probability of treatment being perceived
as helpful did not differ significantly by country income
level (62.8% vs. 70.9%; χ21 = 2.7, p = 0.099).
Helpful GAD treatment across professionals seen
Across all countries, 26.7% (1.0) of respondents who received
treatment said they were helped by the first professional they
saw (Table 2, Part I). The conditional probability of obtaining
helpful treatment from a second professional seen after an
initial unhelpful treatment was 36.6%. Conditional probabil-
ities of obtaining helpful treatment generally declined after
subsequent professionals seen but projected cumulative
probabilities of obtaining helpful treatment rose from 26.7%
after the first professional seen to 53.5% among respondents
who persisted in seeing a second professional and to 96.9%
among those who persisted in seeing up to 10 professionals
after prior unhelpful treatments (Table 2, Part II). These cu-
mulative probabilities were broadly similar for LMICs and
HICs up through three professionals seen (66.9% vs. 68.9%),
after which the number of remaining respondents in LMICs
became too small for analysis (eTable 2).
Persistence with help-seeking for GAD following
treatment failure
Across all countries, 77.3% (1.1) of respondents persisted
in seeing a second professional after initial unhelpful
GAD treatment (Table 3). This proportion was higher in
HICs (79.6% [1.2]) than LMICs (55.8% [3.5]). Condi-
tional probabilities of help-seeking persistence remained
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Table 1 Lifetime prevalence of DSM-5 generalized anxiety disorder (GAD), proportion of respondents with lifetime GAD who
obtained treatment, and proportion of treated respondents who perceived treatment as helpful
Total sample Respondents with lifetime GAD Respondents who obtained treatment for GAD
Prevalence of lifetime GAD Proportion who obtained treatmenta Proportion who perceived treatment as helpfulb
% (SE) (n) % (SE) (n) % (SE) (n)
I. Low/middle-income countries
Sao Paulo, Brazil 5.1 (0.4) (5037) 23.6 (3.5) (280) 71.4 (7.4) (63)
Bulgaria 2.2 (0.2) (6826) 16.8 (3.2) (157) 69.4 (10.0) (27)
Colombia 1.9 (0.3) (4426) 15.8 (4.6) (84) 45.0 (17.4) (15)
Medellin, Colombia 3.8 (0.5) (3261) 17.9 (3.4) (127) 73.7 (9.8) (31)
Iraq 5.0 (0.6) (4332) 22.2 (5.5) (220) 52.5 (13.8) (33)
Lebanon 2.3 (0.3) (2857) 12.4 (4.7) (71) 38.1 (19.1) (9)
Mexico 1.1 (0.2) (5782) 8.5 (3.8) (78) 28.4 (17.6) (8)
Peru 1.0 (0.1) (3930) 23.0 (8.3) (40) 82.1 (8.5) (10)
All 2.8 (0.1) (36,451) 19.2 (1.8) (1057) 62.8 (4.9) (196)
χ27 242.3* 8.4 11.2
II. High-income countries
Argentina 5.2 (0.6) (3927) 34.7 (6.0) (224) 85.1 (6.0) (70)
Australia 8.0 (0.4) (8463) 49.0 (2.5) (713) 76.7 (3.0) (326)
Belgium 3.2 (0.8) (1043) 35.6 (12.5) (62) 33.9 (18.5) (20)
France 6.0 (0.7) (1436) 33.2 (4.4) (159) 71.1 (7.7) (62)
Germany 1.7 (0.4) (1323) 34.2 (8.7) (48) 80.5 (13.3) (19)
Israel 4.4 (0.3) (4859) 36.9 (3.4) (216) 44.6 (5.9) (76)
Italy 1.9 (0.3) (1779) 24.3 (4.8) (78) 89.1 (6.2) (25)
Japan 2.6 (0.3) (4129) 30.9 (4.8) (105) 67.5 (10.2) (30)
Netherlands 3.6 (0.4) (1094) 46.4 (6.3) (95) 88.3 (5.3) (45)
New Zealand 7.9 (0.3) (12,790) 41.2 (1.9) (1084) 68.0 (2.8) (411)
Northern Ireland 6.4 (0.4) (4340) 39.6 (2.3) (334) 70.2 (4.9) (131)
Poland 0.9 (0.1) (10,081) 37.8 (5.0) (90) 73.7 (7.4) (33)
Portugal 6.1 (0.5) (3849) 41.3 (2.7) (269) 73.4 (5.7) (104)
Saudi Arabia 2.3 (0.4) (3638) 27.5 (9.1) (81) 56.7 (17.7) (23)
Spain 1.9 (0.2) (2121) 36.3 (5.0) (114) 90.1 (3.5) (41)
Murcia, Spain 7.0 (0.9) (2621) 37.5 (4.6) (193) 76.4 (9.4) (80)
United States 7.8 (0.3) (9282) 28.1 (2.3) (752) 69.5 (3.2) (205)
All 5.3 (0.1) (76,775) 38.4 (0.9) (4617) 70.9 (1.4) (1701)
% (SE) (n) % (SE) (n) % (SE) (n)
χ216 731.6* 53.7* 54.1*
III. Pooled countries
All countries 4.5 (0.1) (113,226) 34.6 (0.8) (5674) 70.0 (1.4) (1897)
χ224 1276.3* 150.4* 67.0*
Low/middle-income countries vs. high-income countries
χ21 206.6* 63.6* 2.7
Abbreviations. GAD generalized anxiety disorder; SE, standard error
*Significant at the .05 level, two-sided test
aCases are based on three conditions: (i) Respondents obtained GAD treatment; (ii) Year of first GAD treatment ≥1990; and (iii) Age at onset of GAD ≤ Year of first
GAD treatment
bCases are based on four conditions: (i) Respondents obtained GAD treatment; (ii) Year of first GAD treatment ≥1990; and (iii) Age at onset of GAD ≤ Year of first
GAD treatment; and (iv) Respondents obtained helpful treatment
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quite high (81.9–100.0%) in the total sample up through
10 professionals seen. Unlike the situation with cumula-
tive probabilities of obtaining helpful treatment, which,
by definition, either remains the same or rises as the
number of professionals seen increases, the cumulative
probability of help-seeking persistence either remains
the same or decreases as the number of professionals
seen increases. In the total sample, the cumulative prob-
ability of persistence through 10 professionals was
29.7%. We were able to compare respondents in LMICs
to those in high income countries through four profes-
sionals seen, where the cumulative probability of persist-
ence was lower in LMICs (43.2% [5.9]) than in high
income countries (57.5% [2.5]) (eTable 3).
Predictors of obtaining helpful treatment for GAD
We examined predictors of each respondent ever obtain-
ing helpful GAD treatment regardless of number of pro-
fessionals seen (Model 1; Table 4), then examined
predictors separately for the two pathways to helpful
treatment: obtaining helpful treatment from a given pro-
fessional (Model 2; Table 4) and persisting in help-
seeking after prior unhelpful treatment (Model 3; Table
4). We focus on the significant predictors at the person-
level (Model 1; Table 4) and examine how the results in
the decomposed models help explain these person-level
associations. Due to high comorbidity between disorders
and the potential for multicollinearity, we evaluated as-
sociations with comorbid disorders in separate univariate
Table 2 Conditional and cumulative probabilities of obtaining helpful treatment for generalized anxiety disorder after each






treatment (n = 1897)
Number of professionals seen until the respondent obtained helpful treatment % (SE) (n) % (SE)
1 26.7 (1.0) (1897) 26.7 (1.0)
2 36.6 (1.7) (1070) 53.5 (1.6)
3 33.1 (2.4) (585) 68.9 (1.7)
4 29.0 (3.4) (335) 77.9 (1.5)
5 25.2 (3.1) (213) 83.5 (1.4)
6 33.1 (5.1) (136) 89.0 (1.2)
7 16.4 (4.7) (88) 90.8 (1.2)
8 16.6 (3.7) (72) 92.3 (1.1)
9 3.5 (3.4) (59) 92.6 (1.1)
10 57.9 (7.2) (58) 96.9 (0.7)
Abbreviations. SE standard error
Table 3 Conditional and cumulative probabilities of persistence in help-seeking after previous unhelpful treatment, among
respondents with lifetime DSM-5 generalized anxiety disorder who obtained treatment
I. Conditional probabilities of persistence
in help-seeking
II. Cumulative probabilities of
persistence in help-seeking
(n = 1373)
Number of professionals seen after not being helped previously % (SE) (n) % (SE)
2 77.3 (1.1) (1373) 77.3 (1.1)
3 83.4 (1.5) (696) 64.4 (1.9)
4 87.1 (1.8) (385) 56.1 (2.3)
5 83.9 (2.1) (248) 47.1 (2.4)
6 83.8 (2.8) (157) 39.5 (2.6)
7 81.9 (4.9) (102) 32.3 (2.9)
8 94.6 (1.9) (77) 30.6 (2.9)
9 97.0 (0.4) (61) 29.7 (2.9)
10 100.0 (0.0) (58) 29.7 (2.9)
Abbreviations. SE standard error
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and then multivariate models. Only comorbid disorders
that significantly predicted obtaining helpful treatment
in the multivariate models were included in Models 1–3
as individual predictors (eTable 4).
At the person-level, significant predictors of obtaining
helpful treatment were treatment type (χ24 = 12.3, p =
0.015), comorbid panic/agoraphobia (χ21 = 8.9, p =
0.003), and childhood adversities (χ22 = 9.7, p = 0.008).
The association with treatment type was because re-
spondents who received treatment from a mental health
specialist in combination with medication had signifi-
cantly increased relative-odds of obtaining helpful treat-
ment than those who received treatment in the human
services sector (the reference category; OR:1.46; 95% CI:
1.05, 2.02). Decomposition showed that this person-level
association of treatment from a mental health specialist
in combination with the outcome was due to lower
relative-odds of encounter-level helpfulness (OR: 0.76;
95% CI: 0.62, 0.93), but higher relative-odds of treatment
persistence (OR: 2.00; 95% CI: 1.50, 2.67). Comorbid
panic/agoraphobia was associated at the person-level
with having significantly increased relative-odds of
obtaining helpful treatment (OR: 1.79; 95% CI: 1.22,
2.62) due to increased relative-odds of treatment persist-
ence (OR: 2.12; 95% CI: 1.53, 2.94).
Childhood adversities were also important predictors
of treatment helpfulness, but unexpectedly, the pattern
of associations was different for the two classes of adver-
sities. A history of family dysfunction was significantly
associated with reduced relative-odds of obtaining help-
ful treatment at the person-level (OR: 0.75; 95% CI: 0.58,
0.96), whereas a history of other childhood adversities
was significantly associated with increased relative-odds
of obtaining helpful treatment (OR: 1.47; 95% CI: 1.09,
1.99). Decomposition showed that the person-level asso-
ciation of family dysfunction with the outcome was due
to significantly reduced relative-odds of treatment per-
sistence (OR: 0.73; 95% CI: 0.57, 0.93), whereas the
person-level association other childhood adversities with
the outcome was due to significantly increased relative-
odds of treatment persistence (OR: 1.51; 95% CI: 1.10,
2.07). It is noteworthy that the zero- Pearson correlation
between the two CA measures is too low (r = 0.23) to
create an opposite-sign pattern as a methodological
artifact. Consistent with this observation, the same
opposite-sign pattern was also observed in models where
only one of the two CA measures was included.
Although the omnibus χ2 tests for treatment timing
and treatment delay were not significant, there were sig-
nificantly increased relative-odds of both predictors with
significantly decreased relative-odds of with persistence
in help-seeking after an initial unhelpful treatment, were
found for both beginning treatment in more recent years
(2000 or later) and longer treatment delays in obtaining
helpful treatment from a given professional, resulting in
nonsignificant associations at the person-level.
We found significant interactions of treatment type
and childhood adversities with country income level
(eTable 5). These interactions were due to the predictors
being more strongly associated with person-level treat-
ment helpfulness in LMICs than HICs (eTables 6 and 7),
but the significant associations were based on such small
numbers of cases that substantive interpretation is haz-
ardous. Significant interactions were also found between
treatment type and historical time (eTable 8). These
were due to mental health specialist and psychotherapy
treatment and general medical treatment both having in-
creased relative-odds of person-level treatment helpful-
ness only during the years 1990–1999 and receiving
treatment from 2+ types of professionals having in-
creased relative-odds of person-level treatment helpful-
ness only during the years 2000+ (eTables 9 and 10).
Again, though, these interactions were based on rela-
tively small numbers of cases and should be interpreted
with caution.
Discussion
The main findings of the study are as follows. First, only
about one-third of people with GAD reported ever
obtaining treatment, with a lower proportion in LMICs
than HICs (19.2% vs. 38.4%). Second, 70% of those who
received treatment perceived the treatment to be helpful.
This did not vary by country income level. Third, per-
sistence in help-seeking was required to obtain helpful
treatment, as only about one-fourth of patients were
helped by the first professional they saw and about half
by the first two professionals. Projections from our sur-
vival models suggest that up to 10 professionals might
be needed to have a 90% probability of being helped, but
that only 29.7% of patients would persist that long in the
face of repeated unhelpful treatment encounters. Fourth,
only relatively modest predictors were found of obtain-
ing helpful treatment at the person-level, most of which
were important because they predicted persistence ra-
ther than encounter-level treatment helpfulness.
It is encouraging that the large majority (70.0%) of re-
spondents with lifetime DSM-5 GAD who sought treat-
ment eventually obtained treatment they considered
helpful. This means that the majority of patients per-
sisted up to 3–4 professions in the face of initial unhelp-
ful treatment. This is a lower persistence rate than
found in a parallel analysis of specific phobia [37], but a
higher persistence rate than found in parallel analyses of
patients with major depression [20] and PTSD [21], pos-
sibly because depressive and PTSD symptoms are more
likely than anxiety symptoms to lead to discouragement
in help-seeking. Even so, we estimated than only 22.7%
of GAD patients would persist in help-seeking to a point
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where they had near certainty of receiving helpful
treatment.
Our data on the predictors of helpfulness are useful
in beginning to delineate pathways. Patients who re-
ceived treatment from a mental health specialist in
combination with medication had significantly in-
creased relative-odds of obtaining helpful treatment at
the person-level than those who received treatment in
the human services sector. This was due to lower
relative-odds of encounter-level helpfulness, but
higher relative-odds of treatment persistence. Patients
who receive medication in addition to seeing a mental
health specialist may have been more severe than
other patients, resulting in lower relative-odds of
encounter-level helpfulness due to the severity of
their illness, but also more motivation to persist in
help-seeking because of that high severity. Likewise,
panic/agoraphobia was also associated with having
significantly increased relative-odds of obtaining help-
ful treatment at the person-level due to increased
relative-odds of treatment persistence. These individ-
uals may have more chronic and impairing courses of
illness [38] which may motivate them to persist in
help-seeking.
The relationship between childhood adversity and
treatment helpfulness was less straightforward. Family
dysfunction was associated with lower relative-odds of
obtaining helpful treatment due to lower relative-odds of
treatment persistence. In contrast, other childhood ad-
versities were associated with greater relative-odds of
obtaining helpful treatment due to increased relative-
odds of treatment persistence. One possible explanation
for this difference is that the family dysfunction category
included violent and traumatic forms of adversity,
whereas the other childhood adversities category did not
[39]. If this finding is replicated in other studies, future
research should focus on why traumatic childhood
events are associated with lower persistence in help-
seeking, which could inform treatment guidelines.
Important limitations of this study should be noted.
First, there was limited information about the precise
nature of the interventions that respondents received
and no information about sequencing of treatments
across types of providers. Moreover, the treatments were
not randomized nor evaluated in relation to quality of
delivery (treatment integrity) or compliance on the part
of the patient (adherence). Consequently, the relation of
critical dimensions of treatment to helpfulness could not
be discerned. Second, the sample was limited to respon-
dents with onset of GAD treatment after 1990. Recall
may have been biased and influenced evaluations of the
treatments and helpfulness [40]. It is unclear whether
these limitations would lead to upward or downward
bias in estimates of treatment effectiveness at the
encounter level or patient level. Despite these limita-
tions, to our knowledge this is the first study of per-
ceived helpfulness of treatment of GAD. A strength of
the study is including large sample representing multiple
countries and with the ability to evaluate commonalities
and differences among low and middle income and high-
income countries.
RCTs are clearly required to determine the efficacy
and effectiveness of GAD treatments [4–7]. Although
our data do not fill this need, they are important because
they address issues that RCTs cannot. Specifically, RCTs
typically focus on short-term effects (e.g., 3 months), as-
sess mainly symptomatic changes, and exclude many
people who might have more complicated disorders,
such as those with psychiatric comorbidities but who
would benefit from treatment [8]. Our study, in com-
parison, looked at a broad and representative sample
without these exclusionary criteria and included infor-
mation on how patients view their treatment. We would
encourage the assessment of treatment helpfulness in
clinical trials because it is distinguishable from symp-
tomatic change. One can readily conceive of patients
showing similar or identical changes on standardized
symptom measures but in fact profiting in different de-
grees from treatment in their everyday lives and hence
in their views of how much they have been helped [41].
Our findings suggest that treatment guidelines should
not only encourage evidence-based interventions, but
also should emphasize the value of treatment persist-
ence. Our data do not allow us to study new treatments
from the same provider. The persistence we examined
was across providers. It should be noted, though, that
evidence is clear in showing that patients can also be
helped by new treatments from the same provider [42].
Further work is needed to expand GAD care to address
treatment motivations and expectations and to deter-
mine the extent to which interventions to improve GAD
treatment quality and persistence can improve
outcomes.
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